Compared with the control and Lmo treatments, the tumor‐bearing mice treated with Lmo@RBC displayed an obviously high level of IL‐6, IL‐1β, and TNF‐α in blood serum (Figure 23b–d), which was attributed to the high‐efficiency tumor‐homing capability of Lmo@RBC to improve the therapeutic efficiency. This evidence concerns the gene IL1B and neoplasm.